Pyxis Oncology interim CEO to speak at three healthcare conferences

1 min read | Published on 01 Sept 2026, 05:16 PM |Updated on 01 Sept 2026, 05:16 PM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

Key Highlights

Interim CEO Tom Civik to speak at Wells Fargo, Cantor, and H.C. Wainwright conferences
Sessions scheduled for September 10, 11, and 14, 2026, in Boston and New York
Lead candidate MICVO holds FDA Fast Track Designation for R/M HNSCC
Phase 1 monotherapy and Phase 1/2 combination studies ongoing

*this image is generated using AI for illustrative purposes only.

Pyxis Oncology, Inc. (NASDAQ: PYXS) announced that Tom Civik, its interim chief executive officer and director, will participate in fireside chats at three upcoming investor conferences in September 2026.

The clinical-stage biopharmaceutical company aims to engage with investors regarding its development of next-generation therapeutics for difficult-to-treat cancers.

Conference Schedule

Civic will appear at the following events:

Wells Fargo 21st Annual Healthcare Conference: Boston, MA, on Thursday, September 10, 2026, at 10:15 am ET.
2026 Cantor Global Healthcare Conference: New York, NY, on Friday, September 11, 2026, at 10:55 am ET.
H.C. Wainwright 28th Annual Global Investment Conference: New York, NY, on Monday, September 14, 2026, at 9:30 am ET.

Live webcasts and replays of these sessions will be accessible via the Events & Presentations page on Pyxis Oncology’s investor relations website.

Pipeline Update

Pyxis Oncology is advancing micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate targeting extradomain-B of fibronectin (EDB+FN). This target is selectively overexpressed in the tumor microenvironment of various solid tumors but largely absent from normal adult tissues.

MICVO employs a three-pronged mechanism of action: direct cancer cell killing, bystander effect, and immunogenic cell death. The candidate is currently being evaluated as a monotherapy in a Phase 1 clinical study for patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Additionally, MICVO is under investigation in combination with Merck’s KEYTRUDA (pembrolizumab) in a Phase 1/2 study for R/M HNSCC and other solid tumors. The U.S. Food and Drug Administration has granted Fast Track Designation to MICVO for treating adult patients with R/M HNSCC whose disease progressed following platinum-based chemotherapy and anti-PD-(L)1 therapy.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific clinical data or milestones does Pyxis Oncology plan to present at the September 2026 investor conferences to validate the efficacy of MICVO?

How might the results from the combination study with Merck’s KEYTRUDA influence potential partnership discussions or licensing opportunities for Pyxis?

Given the Fast Track Designation for R/M HNSCC, what is the projected timeline for Pyxis to advance MICVO into Phase 2 trials or seek Breakthrough Therapy designation?

Pyxis Oncology files prospectus for 39.2M share sale by existing holders

0 min read | Published on 21 Aug 2026, 02:09 AM |Updated on 21 Aug 2026, 02:09 AM

Reviewed by

Shraddha JScanX News Team

Add as a preferred
source on Google

Key Highlights

Pyxis Oncology filed a prospectus with the SEC for a secondary offering.
The deal involves 39.2 million common shares on behalf of selling shareholders.
Proceeds from the sale will go to the selling shareholders, not the company.

*this image is generated using AI for illustrative purposes only.

Pyxis Oncology Inc. filed a prospectus with the US Securities and Exchange Commission for an offering of 39.2 million common shares on behalf of selling shareholders.

The filing indicates a secondary offering where proceeds will go to existing shareholders rather than the company. The document was lodged under standard SEC regulations for equity resale.

Offering Details

Metric	Value
Shares Offered	39.2 million
Type	Common Shares
Beneficiary	Selling Shareholders
Regulator	US Securities and Exchange Commission

No financial performance data or operational metrics were disclosed in this specific filing notice.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

Which major institutional investors or early backers are likely behind this significant 39.2 million share sell-off, and what does their exit signal about their confidence in Pyxis Oncology's pipeline?

How might the increased share supply from this secondary offering impact Pyxis Oncology's stock price volatility and trading liquidity in the near term?

Given that no proceeds go to the company, will Pyxis Oncology need to pursue additional capital raises or strategic partnerships to fund its ongoing clinical trials and operational expenses?